IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.
- FY26 revenue up 3.4% to $20.5 million
- Net loss shrinks 66% to $2.7 million
- EBITDA loss narrows 85% to $0.9 million
- $7.3 million capex program to expand sterile and solid oral manufacturing
- Three-year target to reach $50 million revenue by FY29
Sharp Earnings Turnaround Signals Strategic Reset Success
IDT Australia Limited (ASX:IDT) has delivered a markedly improved financial performance for the year ended 30 June 2026, showcasing the early fruits of a strategic reset aimed at repositioning the company as a specialist contract development and manufacturing organisation (CDMO) in the Asia-Pacific region. The company’s net loss after tax narrowed by 66.3% to $2.7 million, while EBITDA improved by 85% year-on-year, reducing the loss to just $922,000.
Revenue edged up 3.4% to $20.5 million, driven by stronger contributions from Active Pharmaceutical Ingredients (API) and Speciality Orals verticals, which grew 44% and 49% respectively. Meanwhile, Advanced Therapies (sterile manufacturing) revenue declined 27%, largely due to contract timing rather than demand, with management confident in its future growth prospects.
Focused Growth on High-Margin CDMO Services
The strategic reset has sharpened IDT’s commercial focus on higher-margin CDMO services across API, solid oral, and sterile manufacturing. The API segment, dealing with complex and high-potency small molecule chemistry, is positioned as the foundation for growth, posting a 29% revenue increase to $5.4 million. The solid oral manufacturing vertical capitalised on opportunities in radiopharmaceuticals and medicinal cannabis, with a 52% revenue jump to $5.5 million.
Despite a slight 11% revenue dip in sterile manufacturing to $5.9 million, the company highlights a strong pipeline and growing global demand for mRNA drugs, reinforced by Sanofi designating IDT as a “Preferred Vendor.” This vertical remains a key growth driver for the group.
$7.3 Million Investment to Boost Manufacturing Capacity
IDT has approved a $7.3 million capital investment program, fully funded from its balance sheet and existing debt facilities, to expand and upgrade its sterile and solid oral dose manufacturing capabilities. This includes acquiring world-leading high-tech equipment to produce sterile pre-filled syringes and cartridges at commercial scale, targeting antibody drug conjugates, biologics, biosimilars, mRNA vaccines, and specialty injectables; sectors with acute global CDMO capacity shortages and strong pricing power.
The solid oral upgrade will enhance tablet press, coating, and bottle line capabilities, enabling IDT to compete for more complex oral solid dose contracts including modified-release and fixed-dose combination products. These investments align with IDT’s ambition to capture unmet demand in high-growth biotech clusters internationally.
Strong Balance Sheet and Operational Momentum
At 30 June 2026, IDT held $2.5 million in cash and an additional $7.1 million of undrawn debt facilities, providing $9.7 million in total funds to support growth initiatives. The company also achieved $2.5 million in annualised cost savings, exceeding initial targets by $0.5 million. Operational cash flow turned positive, with a net inflow of $1.07 million for FY26 compared to an outflow of $6.3 million in the prior year.
Leadership changes in the prior year saw Executive Chairman Mark Simari assume CEO responsibilities, steering the company through its strategic reset. The board remains focused on financial discipline, prioritising profit over revenue growth, and optimising capital allocation.
Ambitious $50 Million Revenue Target by FY29
Looking ahead, IDT has set a three-year goal to reach $50 million in annual revenue by FY29, a target grounded in expanding relationships with strategic clients across Australia, the US, Europe, and Asia-Pacific, alongside new customer acquisitions and increased market visibility through targeted conferences and in-market engagement.
The company’s strategic positioning as a specialist in complex small-molecule API and sterile/non-sterile manufacturing, combined with its agile service model, aims to tap into a total addressable market exceeding US$130 billion across its three verticals. This includes a US$47 billion small molecule API segment growing at 7.3% CAGR, a US$46 billion oral solid dosage market at 6.6% CAGR, and a US$38 billion sterile injectables market expanding at 11.2% CAGR.
Industry Recognition and Market Validation
IDT’s transformation and technical excellence were recognised with two awards at the Asia-Pacific RNA Excellence Awards 2026: the Overall RNA Manufacturing Excellence Award and Best Emerging RNA CDMO Award. These accolades underscore the company’s growing reputation among global innovators in RNA therapeutics.
Sanofi’s designation of IDT as a preferred vendor further validates the company’s capabilities and positions it well to capture follow-on and new business in the fast-growing mRNA and biologics sectors.
Risks and Challenges Remain
Despite the positive momentum, IDT faces material risks including customer acquisition and retention, regulatory compliance in a highly regulated industry, competitive pressures from domestic and international CDMOs, rapid technological changes, cybersecurity threats, retention of key personnel, and access to capital. The company’s risk management framework actively monitors these factors, but execution risks remain inherent in achieving the ambitious growth targets.
Investors should also note that no dividends were declared for FY26, reflecting the company’s focus on reinvestment and balance sheet strength.
Bottom Line?
IDT Australia’s FY26 financial turnaround and $7.3 million capex program set a robust foundation for growth, but delivering on the $50 million revenue target by FY29 will require sustained execution amid competitive and regulatory headwinds.
Questions in the middle?
- Can IDT convert its strong pipeline and strategic investments into consistent positive EBITDA in FY27?
- How will the company navigate competitive pressures from larger international CDMOs with potentially lower cost bases?
- What impact will regulatory changes and compliance audits have on IDT’s sterile manufacturing expansion?